Meal Intake for Atherosclerosis
(HPL Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial investigates how varying protein levels in meals affect heart health, focusing on specific immune cells in the blood. Participants will receive one of three liquid meals: a standard protein meal, a high protein meal, or a low protein meal with added leucine, a nutrient that can influence cell activity. The researchers aim to observe how these meals alter blood cell behavior, potentially relating to heart disease risk. Individuals without a history of heart disease, diabetes, high blood pressure, or certain other conditions, and who can consume milk-based meals, might be suitable for this study. As an unphased trial, this study offers a unique opportunity to advance scientific understanding of nutrition and heart health.
Will I have to stop taking my current medications?
Yes, you will need to stop taking certain medications. If you are taking Rapamycin, Torisel, Afinitor, or any statin medication, you cannot participate in the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that high protein diets can have mixed effects on heart health. Some studies have found no link between high protein intake and increased risks of stroke or heart-related deaths. However, other research suggests that consuming a lot of protein might raise the risk of heart attacks or strokes. On the positive side, high protein diets are often associated with effective weight management, which benefits overall health.
For the low protein meal with added leucine, studies in humans remain less clear, but some research in mice suggests that leucine might improve metabolism and lower heart disease risks. Leucine, an amino acid, can influence how cells manage energy.
In summary, while concerns exist about high protein diets and heart health, the evidence is mixed. Adding leucine might offer some benefits, but most data comes from animal studies. Consulting a healthcare provider before joining a trial is always advisable.12345Why are researchers excited about this trial?
Unlike standard treatments for atherosclerosis, which often involve medications like statins to lower cholesterol, this trial is exploring the impact of meal composition on the condition. Researchers are excited about these treatments because they focus on dietary modifications that might offer a non-pharmaceutical approach to managing atherosclerosis. The trial involves different meal compositions: a standard protein meal, a high protein meal, and a low protein meal enhanced with leucine. This approach is unique because it examines how varying protein levels and the addition of leucine could influence heart health, potentially offering a new dietary strategy to combat atherosclerosis.
What evidence suggests that this trial's meals could be effective for atherosclerosis?
This trial will compare the effects of different meal compositions on heart health. Participants will receive one of the following: a standard protein meal, a high protein meal, or a low protein meal with added leucine. Research has shown that high protein diets have mixed effects on heart health. Some studies suggest they might lower blood pressure and aid in weight management. However, other research indicates that high protein diets could increase the risk of heart disease by causing plaque build-up in arteries. Conversely, adding leucine, a type of protein, to a low protein diet has shown promising results in mice, reducing artery plaque and improving cholesterol levels. These findings highlight the complex role of protein and leucine in heart health, and more research is needed to fully understand their effects in humans.24567
Who Is on the Research Team?
Bettina Mittendorfer
Principal Investigator
University of Missouri-Columbia
Are You a Good Fit for This Trial?
This trial is for adults who can consume milk-based liquid meals. It's not suitable for those with a history of organ transplant, diabetes, heart disease, high blood pressure, stroke or cancer. Pregnant individuals and those allergic to meal ingredients or on certain medications like Rapamycin/Sirolimus and statins cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either a low protein liquid meal, a high protein liquid meal, or a low protein liquid meal with additional leucine. Blood is collected before and after meal ingestion to evaluate mTOR signaling.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Meal
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Missouri-Columbia
Lead Sponsor
Washington University School of Medicine
Collaborator